English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
TürkçeHere's What Key Metrics Tell Us About Halozyme Therapeutics (HALO) Q4 Earnings
For the quarter ended December 2025, Halozyme Therapeutics (HALO) reported revenue of $451.77 million, up 51.6% over the same period last year. EPS came in at -$0.24, compared to $1.26 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $448.62 million, representing a surprise of +0.7%. The company delivered an EPS surprise of -111.16%, with the consensus EPS estimate being $2.15.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Halozyme Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Product sales, net: $122.67 million versus $115.69 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +54.6% change. Revenues- Royalties: $257.97 million versus $262.14 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +51.4% change. Revenues- Revenues under collaboration agreements: $71.13 million compared to the $61.31 million average estimate based on four analysts. The reported number represents a change of +47.5% year over year.View all Key Company Metrics for Halozyme Therapeutics here>>>
Shares of Halozyme Therapeutics have returned +11.6% over the past month versus the Zacks S&P 500 composite's -1.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
SeeWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).